BioCardia, Inc. (BCDA)
1.11
+0.03
(+2.78%)
USD |
NASDAQ |
Sep 08, 16:00
1.12
+0.01
(+0.90%)
Pre-Market: 20:00
BioCardia EPS Diluted (Quarterly) : -0.1334 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1334 |
| March 31, 2026 | -0.2089 |
| December 31, 2025 | -0.1845 |
| September 30, 2025 | -0.2362 |
| June 30, 2025 | -0.405 |
| March 31, 2025 | -0.585 |
| December 31, 2024 | -0.499 |
| September 30, 2024 | -0.6143 |
| June 30, 2024 | -0.8769 |
| March 31, 2024 | -1.353 |
| December 31, 2023 | -1.313 |
| September 30, 2023 | -1.786 |
| June 30, 2023 | -2.520 |
| March 31, 2023 | -2.603 |
| December 31, 2022 | -2.478 |
| September 30, 2022 | -2.570 |
| June 30, 2022 | -2.122 |
| March 31, 2022 | -2.922 |
| December 31, 2021 | -3.077 |
| September 30, 2021 | -2.378 |
| June 30, 2021 | -3.068 |
| March 31, 2021 | -2.688 |
| December 31, 2020 | -2.751 |
| September 30, 2020 | -4.574 |
| June 30, 2020 | -6.951 |
| Date | Value |
|---|---|
| March 31, 2020 | -10.09 |
| December 31, 2019 | -7.694 |
| September 30, 2019 | -9.432 |
| June 30, 2019 | -11.60 |
| March 31, 2019 | -11.34 |
| December 31, 2018 | -12.69 |
| September 30, 2018 | -12.50 |
| June 30, 2018 | -10.80 |
| March 31, 2018 | -12.15 |
| December 31, 2017 | -12.15 |
| September 30, 2017 | -10.63 |
| June 30, 2017 | -16.20 |
| March 31, 2017 | -16.20 |
| September 30, 2016 | -278.06 |
| June 30, 2016 | -178.20 |
| March 31, 2016 | -129.60 |
| December 31, 2015 | 0.6318 |
| September 30, 2015 | 0.5832 |
| June 30, 2015 | 0.5184 |
| March 31, 2015 | 0.5346 |
| December 31, 2014 | 0.4212 |
| September 30, 2014 | 0.3078 |
| June 30, 2014 | 0.4698 |
| March 31, 2014 | 0.4536 |
| December 31, 2013 | 0.0324 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cytokinetics, Inc. | -1.505 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.613M |
| Total Expenses (Quarterly) | 1.613M |
| Enterprise Value | 12.81M |
| Earnings Yield | -68.74% |
| Normalized Earnings Yield | -68.74 |